即将招募
Phase 1
药物
clinicaltrials.gov
NCT06941142
海外临床试验导航
乳腺癌
帮助用户按 HER2、三阴性、激素受体、BRCA 和治疗线数拆分检索海外公开临床试验。
Synced trials
当前同步到的治疗类试验
以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。
招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。
状态
全部
试验阶段
全部
治疗类型
全部
国家/地区
全部
即将招募
Phase 2
联合产品
clinicaltrials.gov
NCT06975462
A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT04683679
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07101159
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07673029
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
即将招募
阶段未标明
联合产品
clinicaltrials.gov
NCT07589972
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07441460
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06369285
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06162559
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07294508
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07002177
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04886531
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05982093
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07541079
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04872166
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07207070
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06389006
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07484087
Ablation Compare With Surgery for Early Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05159193
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07635342
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06953882
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07153757
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05986071
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05304962
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04985266
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05190094
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05985655
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT06450314
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06298084
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06245824
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07164976
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
正在招募
Phase 3
联合产品
clinicaltrials.gov
NCT06195709
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
即将招募
Phase 3
药物
clinicaltrials.gov
NCT04736589
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07618390
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07396324
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06313086
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT07137416
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06495541
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05212454
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05891561
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07527806
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06016387
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06797622
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06927180
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07112053
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05760612
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05388500
Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04090567
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06856200
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05286437
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07539753
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05292742
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07102940
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06281210
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05827081
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07510802
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04646759
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07368998
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07423611
ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07163481
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07288359
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07307287
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06500208
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
正在招募
Phase 1, Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07486089
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07263425
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
正在招募
Phase 2
药物其他放疗
clinicaltrials.gov
NCT04899908
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07506876
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT07371585
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT04993014
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06625775
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07413939
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06867484
Breast Re-irradiation After Second Ipsilateral Lumpectomy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05035836
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06993844
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05901935
DP303c in Patients With HER2-positive Advanced Breast Cancer
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT07060807
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06663748
ARX788 in HER2-positive Metastatic Breast Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06475443
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06718335
Pyrotinib in HER2-positive Early Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07116824
HB1801 Combined Treatment of HER2-positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05872347
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07180082
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06263543
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
即将招募
Phase 1, Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT07217990
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04983121
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06110793
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05795101
TRUDI: TDXD+Durva in HER2+/Low IBC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07287917
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05800275
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07336771
JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05461768
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07220135
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07492394
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05524584
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07631052
Capecitabine in ER+/HER2-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06276868
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07616427
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07057427
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06062498
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07340619
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
即将招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT07187752
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06470672
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07005882
Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05098210
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07416253
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07367178
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06964906
Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07394946
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06656624
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06503783
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07589699
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05911958
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05095207
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07100106
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07285382
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
即将招募
阶段未标明
其他放疗
clinicaltrials.gov
NCT06882499
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07417241
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06832202
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06439771
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06750848
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
即将招募
Phase 4
药物
clinicaltrials.gov
NCT04929548
Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07213206
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07100600
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT05996107
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06201234
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06255392
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07290166
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT06179303
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06929325
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06868017
Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06518837
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07405801
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06705127
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07683754
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05872295
IKS014 in Advanced Solid Tumors That Express HER2
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT04225858
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04862663
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05910398
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07647263
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07393321
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04965766
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07647328
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05504707
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06340230
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07065435
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06254690
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07601620
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07518173
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06973525
This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07014410
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06035679
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05979220
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07180160
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05388149
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07205822
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
即将招募
Phase 1
基因治疗
clinicaltrials.gov
NCT06251544
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07340398
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05635487
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT06678269
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05452213
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07406542
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06797635
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT01785420
Pre Operative Trastuzumab in Operable Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07545044
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07294534
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06977893
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05860465
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04481932
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06874933
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04547907
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07459738
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05386108
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06996093
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT07391774
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06992882
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06139107
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05431504
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05901428
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04263298
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06810492
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07335081
ctDNA in HER2+ EBC Neoadjuvant Treatment
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07358377
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07560475
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07081555
A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06254066
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05816655
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06414733
HER-2 B Cell Peptide Vaccine
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05573126
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07377643
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT02535221
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07029399
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06595563
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05744687
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07102381
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05983107
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06202261
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT04923542
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07222215
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07691333
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT04550494
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07129187
SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05838066
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05467891
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06176261
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07005557
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07093931
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06770296
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07071337
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05748834
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07678957
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05698186
Thero2-01S22 in HER2-positive Breast Cancer
即将招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT07177950
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07565324
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT03561740
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07008976
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07400523
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07616453
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
正在招募
Phase 3
生物制剂药物其他
clinicaltrials.gov
NCT06058377
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06686394
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07600164
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07061717
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07299825
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06949410
HER2 Vaccine for Locally Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06757634
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07182721
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07558733
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05314114
Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07618923
Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06830889
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05918328
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06975475
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06568692
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07137871
Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05883852
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07196774
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07281001
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06970912
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05020860
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07310420
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT03740256
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07162259
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07383818
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06441890
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
正在招募
Phase 3
诊断检测药物
clinicaltrials.gov
NCT06065748
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06341621
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07287098
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT04348747
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05861271
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07242118
Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07095023
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06486883
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07152782
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06380751
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05841381
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07136974
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07318805
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06875128
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06950086
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06733233
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07317778
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05900206
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT04158856
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07402473
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06611813
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07619066
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06178159
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07007559
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06429761
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06224673
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07179939
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06341894
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07666555
A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07428018
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05894239
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06641544
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04254263
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07047755
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05508906
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07604571
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04893109
ATEMPT 2.0: Adjuvant T-DM1 vs TH
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05982678
Basket Study for Oligo-metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06923527
Circulating Tumor DNA
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07235618
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06495515
Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07366112
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06339281
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05834764
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07612891
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07407920
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07190443
Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07410559
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07276880
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06217185
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07528716
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07612215
Elacestrant in Advanced Triple Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06001086
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
正在招募
Phase 2
诊断检测药物
clinicaltrials.gov
NCT07459673
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06517212
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07085767
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06837792
Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07047365
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06348134
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT05904964
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06278870
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05955170
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05205200
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05708235
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07658183
A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07630103
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05704829
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05306041
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07427394
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
正在招募
阶段未标明
联合产品
clinicaltrials.gov
NCT07117864
Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
正在招募
阶段未标明
Dietary_Supplement药物
clinicaltrials.gov
NCT06892093
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
即将招募
Phase 4
药物
clinicaltrials.gov
NCT06578299
Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07524322
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06756932
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07494448
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05187832
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07239271
A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04383275
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06167694
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07019337
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06548178
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT07053085
A Study of Surgery and Radiotherapy in People With Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06954961
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07043725
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07498478
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06361940
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06846437
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07173556
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05362760
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT05464810
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06207734
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06259929
NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06234137
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07132242
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05305924
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05683418
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06088056
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06015113
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06374459
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07305246
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT05837455
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06726148
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07062965
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05333328
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07003074
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07610720
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06578286
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05075512
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06891833
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06452394
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07340658
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07647016
Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07258108
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07528898
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05512364
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07330544
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05325632
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05851014
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06439693
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07383506
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT05890287
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07227233
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
即将招募
Phase 1
药物放疗
clinicaltrials.gov
NCT07454668
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07366840
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07615751
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07581795
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07214662
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
即将招募
Phase 3
生物制剂药物手术/操作
clinicaltrials.gov
NCT07578116
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06832904
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05181033
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05403554
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07340541
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07080619
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03915678
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06498154
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07045311
JS207 Combination Therapy in Triple-negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06724263
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06279364
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT05341492
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06224387
CTS2190 Phase I /II Clinical Study in Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06380816
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05627960
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05076760
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07652242
First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04159142
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05318469
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07638852
Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07244874
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05447702
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05806060
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06799065
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06849492
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07552181
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07178171
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05955105
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06125080
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
正在招募
Phase 1
器械药物
clinicaltrials.gov
NCT06246968
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04947189
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03815890
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05760378
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT03808337
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06793553
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06845319
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05866432
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06767527
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06400472
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06538896
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07011654
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07104266
Triple Negative Breast Cancer and Celecoxib. Pilot Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06955156
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04771871
MicroRNA Profiles in Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04230109
Sacituzumab Govitecan In TNBC
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07139470
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT03671044
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
即将招募
Phase 1
生物制剂药物其他
clinicaltrials.gov
NCT07300475
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05746897
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06324240
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07064018
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06547840
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06268327
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06342037
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05192798
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
即将招募
Phase 4
药物手术/操作
clinicaltrials.gov
NCT05843292
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07371208
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07020117
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06690840
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06401005
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04427293
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06078384
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06140576
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT03606967
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06202313
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05749588
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
即将招募
Phase 1, Phase 2
联合产品器械
clinicaltrials.gov
NCT05806385
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT06878625
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT06347068
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07458113
Sac-TMT for Active TNBC Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06245889
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06407310
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07556848
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07486687
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06977542
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05552001
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT04481763
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05821686
Efficacy of Interleukin-2 in Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05660083
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06305962
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07173751
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06910072
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05862064
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07256964
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07111832
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT05698238
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT07108309
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06508216
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06225284
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06632405
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07178730
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07161791
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT03150576
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05035745
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04768426
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06992336
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07153965
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06731153
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05582538
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05451784
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06999187
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06636981
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07297667
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07401537
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT05570253
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
正在招募
Phase 2
Dietary_Supplement药物
clinicaltrials.gov
NCT06649331
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06103864
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06291064
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07623577
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
正在招募
Phase 4
药物
clinicaltrials.gov
NCT04790305
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06355037
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05522491
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06353997
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07299409
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06371807
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07017673
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05862610
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06533384
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07115043
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04315233
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06195618
Personalized Vaccine for TNBC Immunotherapy
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT06606730
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06532812
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07628504
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05973864
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07321015
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06492005
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07545122
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05485766
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT02802423
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06358573
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07679360
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04501523
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06827613
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07423117
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05491226
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05909332
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07271992
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT06975644
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05999149
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06819319
SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07646106
THE-0504 in Patients With Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05215106
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07341867
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06313463
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06908928
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06637306
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07103447
Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06786026
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06434064
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06851299
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07046455
Trop-2 Targeted PET Probes in Advanced TNBC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04137653
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04138719
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05128734
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07441512
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
正在招募
Phase 2
诊断检测药物
clinicaltrials.gov
NCT07069595
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06678048
Arsenous Acid for Refractory Triple-Negative Breast Cancer
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07340424
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT06889610
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT06492759
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07622836
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07040644
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07007780
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06795503
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT07378306
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
正在招募
Phase 1, Phase 2
药物放疗
clinicaltrials.gov
NCT06238921
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07533123
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
正在招募
Phase 1
生物制剂联合产品
clinicaltrials.gov
NCT04282044
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06787339
Capecitabine in Low Risk Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05005403
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07610525
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06367088
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07261631
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06963905
Saci Nivo Rela for TNBC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07394387
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05483491
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07458204
Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05953168
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04159818
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT02926690
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07457359
Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07078604
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06926868
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06165900
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06371274
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04468061
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07669610
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06959537
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06134375
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
即将招募
Phase 3
药物
clinicaltrials.gov
NCT04301739
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06954480
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06189209
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
正在招募
Phase 1, Phase 2
生物制剂器械
clinicaltrials.gov
NCT05329532
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06976944
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05846789
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07466303
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07021261
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07342283
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07015853
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06627712
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05086692
A Beta-only IL-2 ImmunoTherapY Study
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07487519
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07283692
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07151586
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05296564
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05078047
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05550415
The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06318897
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07419880
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04437160
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06099769
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06802757
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07190469
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07623369
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
正在招募
Phase 2
Dietary_Supplement药物其他
clinicaltrials.gov
NCT04677816
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07407517
Adjuvant Intensification for LAR
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06586866
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06471205
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07101614
A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06618287
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06081244
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
正在招募
Phase 1, Phase 2
生物制剂诊断检测
clinicaltrials.gov
NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
正在招募
Phase 4
药物
clinicaltrials.gov
NCT04136782
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
即将招募
Phase 1, Phase 2
药物其他
clinicaltrials.gov
NCT07292142
FMT in Triple Negative Breast Cancer Guided by ctDNA
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05377996
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07528768
Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer
即将招募
Phase 2
放疗
clinicaltrials.gov
NCT07011823
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06685796
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07182149
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07601178
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07517198
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06460298
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
即将招募
Phase 2
放疗
clinicaltrials.gov
NCT06691594
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07187674
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05633654
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05867251
Study of AVZO-021 in Patients With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06817525
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT04722978
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05067530
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06385990
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06617169
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06387628
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
正在招募
EARLY / Phase 1
生物制剂手术/操作
clinicaltrials.gov
NCT06435351
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05954442
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07544056
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06735131
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07016399
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06419621
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05491083
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06682195
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07623642
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT05528133
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07074106
TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
正在招募
Phase 1
联合产品药物
clinicaltrials.gov
NCT05768932
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
正在招募
Phase 1, Phase 2
联合产品药物
clinicaltrials.gov
NCT04333706
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06616987
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07357948
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07054242
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05475678
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05208762
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05422794
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05989828
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07005583
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06545331
Study of XB010 in Subjects With Solid Tumors
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07681297
Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06920810
Viscum Album for TNBC on Adjuvant Pembrolizumab
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07491822
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07188246
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04303988
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06534762
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05706129
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06598046
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06732323
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07413601
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05019690
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06746870
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07372079
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06889688
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06229067
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06365788
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07208149
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07581314
Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06404736
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07351487
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06771609
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06631092
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07281976
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07311993
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07509515
QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05902988
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07195227
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06671262
Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07257484
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06738966
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07088588
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06516289
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
正在招募
Phase 1
器械药物
clinicaltrials.gov
NCT04150042
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06614751
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06666270
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06380660
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
正在招募
阶段未标明
器械手术/操作
clinicaltrials.gov
NCT07292246
A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06064812
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05720260
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06910657
IDOV-Immune for Advanced Solid Tumors
正在招募
Phase 1
生物制剂手术/操作
clinicaltrials.gov
NCT04521764
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04771520
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
即将招募
阶段未标明
其他手术/操作
clinicaltrials.gov
NCT07687225
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT06496724
A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06775236
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03990896
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05628870
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07383649
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07368543
Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT05534438
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05544240
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06718933
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06539559
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07441889
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05535413
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07341737
SL-28 for Advanced Solid Tumours
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05759546
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT04563507
Combined Immunotherapies in Metastatic ER+ Breast Cancer
正在招募
Phase 1
生物制剂药物其他
clinicaltrials.gov
NCT04119024
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
正在招募
阶段未标明
诊断检测手术/操作
clinicaltrials.gov
NCT04671511
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
即将招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06023277
A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07369505
Sapu003 in Advanced mTOR-sensitive Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06653972
Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06081959
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06079983
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05759572
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07679269
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04273061
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07121244
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06835400
Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06010862
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06462079
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06788197
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05232006
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04965064
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07593820
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
正在招募
阶段未标明
器械其他手术/操作
clinicaltrials.gov
NCT05746325
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07354022
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06555068
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07424547
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07292168
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04969835
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07408089
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06774963
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06515470
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06561607
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06545682
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT04990921
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06409390
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06042894
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
即将招募
阶段未标明
放疗
clinicaltrials.gov
NCT06937281
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
即将招募
Phase 1, Phase 2
联合产品
clinicaltrials.gov
NCT07136428
Asciminib in HER2+ Breast Cancer Brain Metastases
正在招募
阶段未标明
器械药物
clinicaltrials.gov
NCT05977036
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06308939
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07492641
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07284836
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06827236
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
即将招募
阶段未标明
放疗
clinicaltrials.gov
NCT06489821
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06488378
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
即将招募
Phase 1
其他手术/操作
clinicaltrials.gov
NCT07590583
Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06784193
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05458674
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07446452
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05470348
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
正在招募
Phase 4
器械药物
clinicaltrials.gov
NCT06230055
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
即将招募
Phase 4
药物
clinicaltrials.gov
NCT05860907
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06609187
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT04529044
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05029999
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07597629
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07461454
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06331169
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT04020575
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05735080
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06680921
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05430399
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06043466
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT06643585
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06188520
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06222879
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT05601440
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07193394
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07648914
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07543536
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
正在招募
EARLY / Phase 1
诊断检测药物
clinicaltrials.gov
NCT04174352
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05440227
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06377852
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03449238
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04802759
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06107686
A Study of YL202 in Selected Patients With Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06771219
SLV-154 Treatment of Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07524855
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05455619
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05297617
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07274852
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05123482
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
正在招募
阶段未标明
器械药物
clinicaltrials.gov
NCT04744506
Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06925984
Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07540572
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
正在招募
阶段未标明
器械手术/操作
clinicaltrials.gov
NCT06532955
The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06533826
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05716516
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06998108
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
正在招募
Phase 3
手术/操作放疗
clinicaltrials.gov
NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06849947
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06547476
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
正在招募
Phase 1
生物制剂其他
clinicaltrials.gov
NCT06746688
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05769010
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03591276
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05092373
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
即将招募
Phase 3
生物制剂其他
clinicaltrials.gov
NCT06434077
Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04222413
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06957886
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07619365
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06265025
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07520760
A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06383767
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
即将招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT05285332
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06462963
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
即将招募
阶段未标明
其他手术/操作
clinicaltrials.gov
NCT07676344
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06842472
PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06778863
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04606446
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05377047
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT05172518
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
即将招募
阶段未标明
放疗
clinicaltrials.gov
NCT06611306
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06839560
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT02830724
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06075810
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06268665
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06642545
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
正在招募
Phase 3
其他手术/操作放疗
clinicaltrials.gov
NCT06500481
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05256745
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07389733
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07150208
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06582017
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07647029
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
即将招募
Phase 1
手术/操作放疗
clinicaltrials.gov
NCT06982222
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
正在招募
Phase 2
其他手术/操作放疗
clinicaltrials.gov
NCT05301881
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07467330
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07203729
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT05753657
A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06452706
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05877599
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
即将招募
阶段未标明
手术/操作放疗
clinicaltrials.gov
NCT06383663
Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast Cancer
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07580833
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04819243
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT05372640
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06026657
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06418594
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06193525
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
正在招募
Phase 2
药物
clinicaltrials.gov
NCT02422641
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT03646955
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06543992
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06493864
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04115306
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06126406
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT06135714
Metastasis-directed Therapy for Oligometastases of Breast Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07156253
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06665178
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT05693766
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
即将招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT07260058
Immune Cell Therapy for Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06533332
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
正在招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06143553
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
正在招募
Phase 2
生物制剂手术/操作放疗
clinicaltrials.gov
NCT06860815
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06750484
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07390838
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06165419
Definitive Radiation for High-Risk Spine Metastases
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06679036
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05530057
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07394218
ctDNA-guided Treatment Decision-making
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT03412877
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07024173
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
正在招募
阶段未标明
其他手术/操作放疗
clinicaltrials.gov
NCT06144346
Metastases Directed Therapy for Oligometastatic Breast Cancer
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT06691035
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07395336
Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06942234
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05696626
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07410676
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06471673
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06105684
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05183126
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
第 1 页
没有符合当前筛选条件的试验。
Subtypes
建议拆分方向
HER2 阳性乳腺癌 HER2-positive breast cancer三阴性乳腺癌 triple-negative breast cancer / TNBC激素受体阳性 HR-positive breast cancerER-positivePR-positiveBRCA mutation转移性乳腺癌 metastatic breast cancerCDK4/6First lineSecond line
Keywords
英文搜索关键词
Keyword guide
这些关键词怎么理解
| 术语 | 中文意思 | 对找临床试验有什么用 |
|---|---|---|
| HER2 阳性乳腺癌 / HER2-positive breast cancer | 癌细胞 HER2 蛋白表达高。HER2 是一个促进细胞生长的受体。 | 可以找 HER2 靶向药试验，比如 trastuzumab、pertuzumab、T-DXd 等相关试验。 |
| 三阴性乳腺癌 / TNBC | ER 阴性、PR 阴性、HER2 阴性。也就是三种常见靶点都没有。 | 通常会找免疫治疗、ADC、化疗组合、PARP 抑制剂等试验。 |
| 激素受体阳性 / HR-positive breast cancer | ER 或 PR 任意一个阳性，都可以叫 HR-positive。 | 常见方向是内分泌治疗、CDK4/6、PI3K/AKT/mTOR、SERD 等。 |
| ER-positive | 雌激素受体阳性。癌细胞可能受雌激素刺激生长。 | 可以找内分泌治疗相关试验。 |
| PR-positive | 孕激素受体阳性。经常和 ER 一起看。 | 也属于激素受体相关信息。 |
| BRCA mutation | BRCA1 或 BRCA2 基因突变。可能是遗传性，也可能是肿瘤里的体细胞突变。 | 可以找 PARP 抑制剂、DNA 损伤修复相关试验。 |
| 转移性乳腺癌 / metastatic breast cancer | 癌症已经扩散到乳房以外的远处器官，比如骨、肝、肺、脑等。 | 很多试验会限定 metastatic 或 advanced 患者。 |
| CDK4/6 | 一类细胞周期相关靶点。CDK4/6 抑制剂常用于 HR-positive、HER2-negative 转移性乳腺癌。 | 可以找 palbociclib、ribociclib、abemaciclib 等相关试验。 |
| First line | 一线治疗。通常指确诊晚期或转移后，第一次系统治疗方案。 | 试验可能要求患者未接受过晚期一线治疗。 |
| Second line | 二线治疗。通常是一线治疗失败、进展或不能耐受后，换的下一套方案。 | 很多试验会写 after progression on first-line therapy。 |
Recruitment status
常见招募状态
| Recruiting | 正在招募，可能仍可申请参加。 |
| Not yet recruiting | 尚未开始招募，可关注后续开放时间。 |
| Active, not recruiting | 试验仍在进行，但通常不再招新患者。 |
| Completed | 试验已经完成。 |
| Terminated | 试验提前终止。 |
| Unknown | 公开页面上的状态不明确或未及时更新。 |
Before contact
联系前准备资料
- 病理诊断报告
- 影像报告：CT / MRI / PET-CT
- 既往治疗记录
- 用药历史
- 基因检测报告
- 最近血液检查结果
- 出院小结
- 主治医生英文病情摘要，如果有
- 护照和签证情况，如果考虑出国
Filters
搜索时重点关注
- Recruiting / Not yet recruiting
- Location
- Age
- Phase
- Inclusion Criteria
- Exclusion Criteria
- Prior treatments
- Biomarker / mutation requirements
- ECOG performance status
- 是否接受 international patients
- 是否需要长期停留在试验所在地
- 费用、保险、翻译、住宿和陪护安排
Ask your doctor
可以带去问医生的问题
- 我的病理类型是否符合这个试验？
- 我之前用过的药会不会影响入组？
- 我是否需要做基因检测？
- 这个试验是几期？主要目的是什么？
- 参加试验会不会影响当前治疗？
- 如果去国外参加，风险和成本大概有哪些？
- 研究团队是否接受海外患者？
请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。